Pharmaceuticals

Fangsheng Pharmaceutical

Fangsheng Pharmaceutical released FY2025 Q4 earnings on April 24 Pre-Market (BJT), actual revenue CNY 493.13 M, actual EPS CNY 0.0883

Fangsheng Pharmaceutical released FY2025 earnings on April 24 Pre-Market (BJT), actual revenue CNY 1.746 B (forecast CNY 1.815 B), actual EPS CNY 0.7 (forecast CNY 0.695)

Fangsheng Pharmaceutical released FY2026 Q1 earnings on April 24 After-Market (BJT), actual revenue CNY 462.77 M, actual EPS CNY 0.2

Fangsheng Pharmaceutical to Release FY2026 Q1 Earnings on April 25 After-Market (BJT)

Fangsheng Pharmaceutical to Release FY2025 Earnings on April 25 Pre-Market (BJT), Forecast Revenue CNY 1.815 B, EPS CNY 0.695

Fangsheng Pharmaceutical released FY2025 Q3 earnings on October 23 After-Market (BJT), actual revenue CNY 419.07 M, actual EPS CNY 0.2193

Fangsheng Pharmaceutical released FY2025 9 Months earnings on October 23 After-Market (BJT), actual revenue CNY 1.253 B, actual EPS CNY 0.6091

Fangsheng Pharmaceutical to Release FY2025 Q3 Earnings on October 24 After-Market (BJT)

Fangsheng Pharmaceutical released FY2025 Semi-Annual Earnings on August 28 After-Market (BJT), Actual Revenue: CNY 834.25M, Actual EPS: CNY 0.39

Fangsheng Pharmaceutical released FY2025 Q2 earnings on August 28 After-Market (BJT), actual revenue CNY 416.17 M, actual EPS CNY 0.1898

Fangsheng Pharmaceutical to Release FY2025 Semi-Annual Earnings on August 29, 2025 (BJT)

Fangsheng Pharmaceutical's subsidiary's herbal innovation drug Ziyin Granules approved for clinical trials

Founder of Fangsheng Pharmaceutical Released on Bail for Insider Trading

Fangsheng Pharmaceutical's Innovative Traditional Chinese Medicine XinQin Heat-Relieving Granules Approved for Clinical Trials

Fangsheng Pharmaceutical Signs Supplemental Agreement with Kangyi Pharmaceutical and Completes Registration of Hong Kong Joint Venture Subsidiary

Fangsheng Pharmaceutical's Subsidiary Approved to Produce New Traditional Chinese Medicine

Fangsheng Pharmaceutical Adds Ophthalmology Concept

Affinipharm Group's Chairman's Relatives Increased Shareholding by 413,300 Shares

Zhang Zuruo Increases Shares in Fangsheng Pharmaceutical

Fangsheng Pharmaceutical's Xiaoer Jingxin Zhike Granules Phase II Clinical Trial Success

603998

According to the Zhitong Finance APP, Fangsheng Pharmaceutical disclosed its third-quarter report for 2025. The company achieved revenue of 1.253 billion yuan in the first three quarters, a year-on-year decrease of 7.02%; the net profit attributable to shareholders of the listed company was 268 million yuan, a year-on-year increase of 17.6%; the net profit excluding non-recurring gains and losses was 213 million yuan, a year-on-year increase of 30.54%; the basic earnings per share were 0.61 yuan

Zhitong

Fangsheng Pharmaceutical released its performance for the first three quarters, with a net profit attributable to the parent company of 268 million yuan, a year-on-year increase of 17.6%

According to the Zhitong Finance APP, Fangsheng Pharmaceutical announced that its wholly-owned subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd. (referred to as "Fangsheng Jianmeng"), has received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration, approving the clinical trial of this product for prostate cancer

Fangsheng Pharmaceutical: Clinical trial for Relugolix tablets approved

Fangsheng Pharmaceutical announced that it has signed a technology transfer contract with Yifan Pharmaceutical to acquire the marketing authorization for "Compound Dexamethasone Acetate Cream." This move aims to enrich the company's product line, promote the development strategy of innovative traditional Chinese medicine, and is expected to bring new profit growth points to the company, enhancing its market competitiveness

Fangsheng Pharmaceutical plans to acquire the marketing authorization for "Compound Acetate Dexamethasone Cream."

Fangsheng Pharmaceutical announced that its research and development of the traditional Chinese medicine innovative drug Zhilong Tongluo Pian has obtained the Phase II clinical research report. This drug is suitable for various symptoms during the recovery period of cerebral infarction, and the trial results show good safety, as well as positive effects in improving neurological function and quality of life. It is recommended to continue with Phase III clinical research

Fangsheng Pharmaceutical: The summary report of the Phase II clinical trial for Zhilong Tongluo tablets has been obtained

According to the Zhitong Finance APP, Fangsheng Pharmaceutical announced that its holding subsidiary, Guangdong Fangsheng Rongo Pharmaceutical Co., Ltd. (referred to as "Fangsheng Rongo"), has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for its innovative traditional Chinese medicine research and development project, gynecological hemostatic and analgesic granules. The National Medical Products Administration has agreed to conduct Phase II and III clinical trials based on further improvement of the clinical trial protocol

Fangsheng Pharmaceutical: Clinical trial for gynecological hemostatic and analgesic granules approved

Fangsheng Pharmaceutical announced that in the first half of 2025, operating revenue was 834 million yuan, a year-on-year decrease of 8.35%. Net profit was 169 million yuan, a year-on-year increase of 23.67%. The company plans to distribute a cash dividend of 1.5 yuan for every 10 shares to all shareholders

Fangsheng Pharmaceutical: Net profit in the first half of 2025 increased by 23.67% year-on-year

600232

300199

The industrial hemp sector has undergone significant adjustments, GETM has hit the limit down, and HYBIO, Fangsheng Pharmaceutical, and Bohai Chemical have followed suit

GETM

HYBIO

The industrial hemp sector has undergone significant adjustments, and GETM has hit the daily limit down

Fangsheng Pharmaceutical's subsidiary Fangsheng Rongke's innovative traditional Chinese medicine research and development project Ziying Granules has recently received the clinical trial approval notice from the National Medical Products Administration. This drug aims to treat the sequelae of pelvic inflammatory disease and is mainly used to alleviate symptoms such as chronic pelvic pain

Fangsheng Pharmaceutical's subsidiary has received the drug clinical trial approval notice for its traditional Chinese medicine innovation drug research and development project

Fangsheng Pharmaceutical's controlling shareholder Zhang Qinghua received a penalty decision from the China Securities Regulatory Commission in 2021 for suspected insider trading. On August 6, 2025, Zhang Qinghua received a decision from the Changsha Public Security Bureau for bail pending trial and is now on bail. Zhang Qinghua currently does not hold any position in the company, and this incident is unrelated to the company's daily operations and will not affect the company's business and financial condition

Fangsheng Pharmaceutical: Actual controller Zhang Qinghua has been released on bail pending trial

On July 22, Fangsheng Pharmaceutical announced that the company and its wholly-owned subsidiary Tengwangge Pharmaceutical signed the "Drug Marketing Authorization Transfer Agreement" to transfer the ownership of the "Qiangli Pipa Lu" drug variety to Kangpu Pharmaceutical at a price not lower than the company's cost price, with the transaction amount within the approval authority of the chairman. This transaction aims to improve asset operation efficiency and initiate strategic cooperation

Fangsheng Pharmaceutical(603998.SH)